

# Joel Tarning

## List of Publications by Year in descending order

Source: <https://exaly.com/author-pdf/9367589/publications.pdf>

Version: 2024-02-01

160  
papers

11,156  
citations

76326

40  
h-index

33894

99  
g-index

169  
all docs

169  
docs citations

169  
times ranked

11857  
citing authors

#	ARTICLE	IF	CITATIONS
1	Mechanistic Modeling of Primaquine Pharmacokinetics, Gametocytocidal Activity, and Mosquito Infectivity. <i>Clinical Pharmacology and Therapeutics</i> , 2022, 111, 676-685.	4.7	1
2	The Effect of Regularly Dosed Acetaminophen vs No Acetaminophen on Renal Function in <i>Plasmodium knowlesi</i> Malaria (PACKNOW): A Randomized, Controlled Trial. <i>Clinical Infectious Diseases</i> , 2022, 75, 1379-1388.	5.8	10
3	Temporal distribution of <i>Plasmodium falciparum</i> recrudescence following artemisinin-based combination therapy: an individual participant data meta-analysis. <i>Malaria Journal</i> , 2022, 21, 106.	2.3	1
4	Ribavirin for treating Lassa fever: A systematic review of pre-clinical studies and implications for human dosing. <i>PLoS Neglected Tropical Diseases</i> , 2022, 16, e0010289.	3.0	17
5	Drug development for the treatment of onchocerciasis: Population pharmacokinetic and adverse events modeling of emodepside. <i>PLoS Neglected Tropical Diseases</i> , 2022, 16, e0010219.	3.0	2
6	Population Pharmacodynamic Modeling of Eflornithine-Based Treatments Against Late-Stage Gambiense Human African Trypanosomiasis and Efficacy Predictions of L-eflornithine-Based Therapy. <i>AAPS Journal</i> , 2022, 24, 48.	4.4	0
7	Triple therapy with artemether+lumefantrine plus amodiaquine versus artemether+lumefantrine alone for artemisinin-resistant, uncomplicated <i>falciparum</i> malaria: an open-label, randomised, multicentre trial. <i>Lancet Infectious Diseases</i> , The, 2022, 22, 867-878.	9.1	27
8	The oral protease inhibitor (PF-07321332) protects Syrian hamsters against infection with SARS-CoV-2 variants of concern. <i>Nature Communications</i> , 2022, 13, 719.	12.8	86
9	Pharmacometric and Electrocardiographic Evaluation of Chloroquine and Azithromycin in Healthy Volunteers. <i>Clinical Pharmacology and Therapeutics</i> , 2022, 112, 824-835.	4.7	3
10	Simultaneous and enantiospecific quantification of primaquine and carboxyprimaquine in human plasma using liquid chromatography-tandem mass spectrometry. <i>Malaria Journal</i> , 2022, 21, .	2.3	3
11	Pharmacokinetic considerations in seasonal malaria chemoprevention. <i>Trends in Parasitology</i> , 2022, 38, 673-682.	3.3	9
12	Response to "Pharmacometric Approach to Evaluate Drug Dosing Adherence". <i>Clinical Pharmacology and Therapeutics</i> , 2021, 110, 24-25.	4.7	0
13	Identification of the metabolites of ivermectin in humans. <i>Pharmacology Research and Perspectives</i> , 2021, 9, e00712.	2.4	21
14	Piperaquine Pharmacokinetics during Intermittent Preventive Treatment for Malaria in Pregnancy. <i>Antimicrobial Agents and Chemotherapy</i> , 2021, 65, .	3.2	10
15	A Physiologically-Based Pharmacokinetic Framework for Prediction of Drug Exposure in Malnourished Children. <i>Pharmaceutics</i> , 2021, 13, 204.	4.5	5
16	Semimechanistic Pharmacokinetic and Pharmacodynamic Modeling of Piperaquine in a Volunteer Infection Study with <i>Plasmodium falciparum</i> Blood-Stage Malaria. <i>Antimicrobial Agents and Chemotherapy</i> , 2021, 65, .	3.2	3
17	Pharmacokinetic Study of Rectal Artesunate in Children with Severe Malaria in Africa. <i>Antimicrobial Agents and Chemotherapy</i> , 2021, 65, .	3.2	11
18	Structure-switching aptamer sensors for the specific detection of piperaquine and mefloquine. <i>Science Translational Medicine</i> , 2021, 13, .	12.4	26

#	ARTICLE	IF	CITATIONS
19	Development and Validation of an <i>In Silico</i> Decision Tool To Guide Optimization of Intravenous Artesunate Dosing Regimens for Severe Falciparum Malaria Patients. <i>Antimicrobial Agents and Chemotherapy</i> , 2021, 65, .	3.2	1
20	High Cure Rates for Hepatitis C Virus Genotype 6 in Advanced Liver Fibrosis With 12 Weeks Sofosbuvir and Daclatasvir: The Vietnam SEARCH Study. <i>Open Forum Infectious Diseases</i> , 2021, 8, ofab267.	0.9	6
21	Study protocol: an open-label individually randomised controlled trial to assess the efficacy of artemether-lumefantrine prophylaxis for malaria among forest goers in Cambodia. <i>BMJ Open</i> , 2021, 11, e045900.	1.9	7
22	High-throughput quantitation method for amodiaquine and desethylamodiaquine in plasma using supported liquid extraction technology. <i>Journal of Chromatography B: Analytical Technologies in the Biomedical and Life Sciences</i> , 2021, 1179, 122887.	2.3	3
23	Determinants of Primaquine and Carboxyprimaquine Exposures in Children and Adults with <i>Plasmodium vivax</i> Malaria. <i>Antimicrobial Agents and Chemotherapy</i> , 2021, 65, e0130221.	3.2	10
24	Development of weight and age-based dosing of daily primaquine for radical cure of vivax malaria. <i>Malaria Journal</i> , 2021, 20, 366.	2.3	3
25	Metabolomics reveal alterations in arachidonic acid metabolism in <i>Schistosoma mekongi</i> after exposure to praziquantel. <i>PLoS Neglected Tropical Diseases</i> , 2021, 15, e0009706.	3.0	5
26	Arterolaneâ€“piperazineâ€“mefloquine versus arterolaneâ€“piperazine and artemetherâ€“lumefantrine in the treatment of uncomplicated <i>Plasmodium falciparum</i> malaria in Kenyan children: a single-centre, open-label, randomised, non-inferiority trial. <i>Lancet Infectious Diseases</i> , The, 2021, 21, 1395-1406.	9.1	20
27	Assessment of the amino acid profile in Thai patients with type 2 diabetes mellitus using liquid chromatography-mass spectrometry. <i>International Health</i> , 2021, 13, 367-373.	2.0	1
28	Combining antimalarial drugs and vaccine for malaria elimination campaigns: a randomized safety and immunogenicity trial of RTS,S/AS01 administered with dihydroartemisinin, piperazine, and primaquine in healthy Thai adult volunteers. <i>Human Vaccines and Immunotherapeutics</i> , 2020, 16, 33-41.	3.3	9
29	Safety, Pharmacokinetics, and Mosquitoâ€“Lethal Effects of Ivermectin in Combination With Dihydroartemisininâ€“Piperazine and Primaquine in Healthy Adult Thai Subjects. <i>Clinical Pharmacology and Therapeutics</i> , 2020, 107, 1221-1230.	4.7	30
30	Adherence and Population Pharmacokinetic Properties of Amodiaquine When Used for Seasonal Malaria Chemoprevention in African Children. <i>Clinical Pharmacology and Therapeutics</i> , 2020, 107, 1179-1188.	4.7	20
31	<i>CYP2B6</i> *6 Genotype Specific Differences in Artemetherâ€“Lumefantrine Disposition in Healthy Volunteers. <i>Journal of Clinical Pharmacology</i> , 2020, 60, 351-360.	2.0	3
32	Effect of Hydroxychloroquine in Hospitalized Patients with Covid-19. <i>New England Journal of Medicine</i> , 2020, 383, 2030-2040.	27.0	1,013
33	Phase 2a, open-label, dose-escalating, multi-center pharmacokinetic study of favipiravir (T-705) in combination with oseltamivir in patients with severe influenza. <i>EBioMedicine</i> , 2020, 62, 103125.	6.1	36
34	Population Pharmacokinetic Properties of Antituberculosis Drugs in Vietnamese Children with Tuberculous Meningitis. <i>Antimicrobial Agents and Chemotherapy</i> , 2020, 65, .	3.2	17
35	COVID-19 prevention and treatment: A critical analysis of chloroquine and hydroxychloroquine clinical pharmacology. <i>PLoS Medicine</i> , 2020, 17, e1003252.	8.4	86
36	A Randomized Controlled Trial of Three- versus Five-Day Artemether-Lumefantrine Regimens for Treatment of Uncomplicated <i>Plasmodium falciparum</i> Malaria in Pregnancy in Africa. <i>Antimicrobial Agents and Chemotherapy</i> , 2020, 64, .	3.2	22

#	ARTICLE	IF	CITATIONS
37	Pooled Multicenter Analysis of Cardiovascular Safety and Population Pharmacokinetic Properties of Piperaquine in African Patients with Uncomplicated Falciparum Malaria. <i>Antimicrobial Agents and Chemotherapy</i> , 2020, 64, .	3.2	5
38	Efficacy and tolerability of artemisinin-based and quinine-based treatments for uncomplicated falciparum malaria in pregnancy: a systematic review and individual patient data meta-analysis. <i>Lancet Infectious Diseases</i> , The, 2020, 20, 943-952.	9.1	25
39	Differential Impact of Nevirapine on Artemether-Lumefantrine Pharmacokinetics in Individuals Stratified by <i>CYP2B6</i> c.516G>T Genotypes. <i>Antimicrobial Agents and Chemotherapy</i> , 2020, 64, .	3.2	4
40	Triple artemisinin-based combination therapies versus artemisinin-based combination therapies for uncomplicated <i>Plasmodium falciparum</i> malaria: a multicentre, open-label, randomised clinical trial. <i>Lancet</i> , The, 2020, 395, 1345-1360.	13.7	182
41	Factors affecting the electrocardiographic QT interval in malaria: A systematic review and meta-analysis of individual patient data. <i>PLoS Medicine</i> , 2020, 17, e1003040.	8.4	20
42	High-Dose Chloroquine for Uncomplicated <i>Plasmodium falciparum</i> Malaria Is Well Tolerated and Causes Similar QT Interval Prolongation as Standard-Dose Chloroquine in Children. <i>Antimicrobial Agents and Chemotherapy</i> , 2020, 64, .	3.2	21
43	Pharmacokinetics and Pharmacodynamics of Intensive Antituberculosis Treatment of Tuberculous Meningitis. <i>Clinical Pharmacology and Therapeutics</i> , 2020, 107, 1023-1033.	4.7	28
44	An Individual Participant Data Population Pharmacokinetic Meta-analysis of Drug-Drug Interactions between Lumefantrine and Commonly Used Antiretroviral Treatment. <i>Antimicrobial Agents and Chemotherapy</i> , 2020, 64, .	3.2	14
45	Concentration-dependent mortality of chloroquine in overdose. <i>ELife</i> , 2020, 9, .	6.0	21
46	Determinants of dihydroartemisinin-piperaquine treatment failure in <i>Plasmodium falciparum</i> malaria in Cambodia, Thailand, and Vietnam: a prospective clinical, pharmacological, and genetic study. <i>Lancet Infectious Diseases</i> , The, 2019, 19, 952-961.	9.1	252
47	A validation study of microscopy versus quantitative PCR for measuring <i>Plasmodium falciparum</i> parasitemia. <i>Tropical Medicine and Health</i> , 2019, 47, 49.	2.8	9
48	Optimal dosing of dihydroartemisinin-piperaquine for seasonal malaria chemoprevention in young children. <i>Nature Communications</i> , 2019, 10, 480.	12.8	28
49	Pharmacokinetic-Pharmacodynamic Assessment of the Hepatic and Bone Marrow Toxicities of the New Trypanoside Fexinidazole. <i>Antimicrobial Agents and Chemotherapy</i> , 2019, 63, .	3.2	17
50	Sequential Open-Label Study of the Safety, Tolerability, and Pharmacokinetic Interactions between Dihydroartemisinin-Piperaquine and Mefloquine in Healthy Thai Adults. <i>Antimicrobial Agents and Chemotherapy</i> , 2019, 63, .	3.2	9
51	Severe Acute Malnutrition Results in Lower Lumefantrine Exposure in Children Treated With Artemether-Lumefantrine for Uncomplicated Malaria. <i>Clinical Pharmacology and Therapeutics</i> , 2019, 106, 1299-1309.	4.7	27
52	Amino acid derangements in adults with severe falciparum malaria. <i>Scientific Reports</i> , 2019, 9, 6602.	3.3	17
53	High sensitivity methods to quantify chloroquine and its metabolite in human blood samples using LC-MS/MS. <i>Bioanalysis</i> , 2019, 11, 333-347.	1.5	26
54	Pooled Population Pharmacokinetic Analysis of Tribendimidine for the Treatment of <i>Opisthorchis viverrini</i> Infections. <i>Antimicrobial Agents and Chemotherapy</i> , 2019, 63, .	3.2	6

#	ARTICLE	IF	CITATIONS
55	Piperaquine concentration and malaria treatment outcomes in Ugandan children treated for severe malaria with intravenous Artesunate or quinine plus Dihydroartemisinin-Piperaquine. BMC Infectious Diseases, 2019, 19, 1025.	2.9	4
56	Chloroquine Versus Dihydroartemisinin-Piperaquine With Standard High-dose Primaquine Given Either for 7 Days or 14 Days in Plasmodium vivax Malaria. Clinical Infectious Diseases, 2019, 68, 1311-1319.	5.8	49
57	Identifying the Components of Acidosis in Patients With Severe Plasmodium falciparum Malaria Using Metabolomics. Journal of Infectious Diseases, 2019, 219, 1766-1776.	4.0	35
58	Drug Interactions between Dolutegravir and Artemether-Lumefantrine or Artesunate-Amodiaquine. Antimicrobial Agents and Chemotherapy, 2019, 63, .	3.2	16
59	Optimization of dosing regimens of isoniazid and rifampicin in children with tuberculosis in India. British Journal of Clinical Pharmacology, 2019, 85, 644-654.	2.4	16
60	Population pharmacokinetics of artesunate and dihydroartemisinin in pregnant and non-pregnant women with uncomplicated Plasmodium falciparum malaria in Burkina Faso: an open label trial. Wellcome Open Research, 2019, 4, 45.	1.8	1
61	Pharmacokinetics of Oral Tenofovir Disoproxil Fumarate in Pregnancy and Lactation: A Systematic Review. Antiviral Therapy, 2019, 24, 529-540.	1.0	12
62	Modeling the dynamics of Plasmodium falciparum gametocytes in humans during malaria infection. ELife, 2019, 8, .	6.0	36
63	Clinically Relevant Drug Interactions for Malaria. , 2019, , 1-11.		0
64	Population Pharmacokinetic Properties of Sulfadoxine and Pyrimethamine: a Pooled Analysis To Inform Optimal Dosing in African Children with Uncomplicated Malaria. Antimicrobial Agents and Chemotherapy, 2018, 62, .	3.2	18
65	Characterizing Blood-Stage Antimalarial Drug MIC Values <i>In Vivo</i> Using Reinfection Patterns. Antimicrobial Agents and Chemotherapy, 2018, 62, .	3.2	12
66	Treatment of uncomplicated and severe malaria during pregnancy. Lancet Infectious Diseases, The, 2018, 18, e133-e146.	9.1	31
67	Primaquine Pharmacokinetics in Lactating Women and Breastfed Infant Exposures. Clinical Infectious Diseases, 2018, 67, 1000-1007.	5.8	26
68	Acetaminophen as a Renoprotective Adjunctive Treatment in Patients With Severe and Moderately Severe Falciparum Malaria: A Randomized, Controlled, Open-Label Trial. Clinical Infectious Diseases, 2018, 67, 991-999.	5.8	44
69	Model-Informed Drug Development for Malaria Therapeutics. Annual Review of Pharmacology and Toxicology, 2018, 58, 567-582.	9.4	21
70	Quantitation of paracetamol by liquid chromatography–mass spectrometry in human plasma in support of clinical trial. Future Science OA, 2018, 4, FSO331.	1.9	8
71	Effect of Antiretroviral Therapy on Plasma Concentrations of Chloroquine and Desethyl-chloroquine. Clinical Infectious Diseases, 2018, 67, 1617-1620.	5.8	4
72	Population Pharmacokinetics of Artemether, Dihydroartemisinin, and Lumefantrine in Rwandese Pregnant Women Treated for Uncomplicated Plasmodium falciparum Malaria. Antimicrobial Agents and Chemotherapy, 2018, 62, .	3.2	15

#	ARTICLE	IF	CITATIONS
73	Acidosis and acute kidney injury in severe malaria. <i>Malaria Journal</i> , 2018, 17, 128.	2.3	9
74	Population pharmacokinetic and pharmacodynamic properties of artesunate in patients with artemisinin sensitive and resistant infections in Southern Myanmar. <i>Malaria Journal</i> , 2018, 17, 126.	2.3	15
75	Population Pharmacokinetics of the Antimalarial Amodiaquine: a Pooled Analysis To Optimize Dosing. <i>Antimicrobial Agents and Chemotherapy</i> , 2018, 62, .	3.2	21
76	Enantiospecific pharmacokinetics and drug-drug interactions of primaquine and blood-stage antimalarial drugs. <i>Journal of Antimicrobial Chemotherapy</i> , 2018, 73, 3102-3113.	3.0	20
77	Comparison of the Cumulative Efficacy and Safety of Chloroquine, Artesunate, and Chloroquine-Primaquine in <i>Plasmodium vivax</i> Malaria. <i>Clinical Infectious Diseases</i> , 2018, 67, 1543-1549.	5.8	52
78	Promising approach to reducing Malaria transmission by ivermectin: Sporontocidal effect against <i>Plasmodium vivax</i> in the South American vectors <i>Anopheles aquasalis</i> and <i>Anopheles darlingi</i> . <i>PLoS Neglected Tropical Diseases</i> , 2018, 12, e0006221.	3.0	37
79	Artemether-lumefantrine dosing for malaria treatment in young children and pregnant women: A pharmacokinetic-pharmacodynamic meta-analysis. <i>PLoS Medicine</i> , 2018, 15, e1002579.	8.4	47
80	Prediction of Improved Antimalarial Chemoprevention with Weekly Dosing of Dihydroartemisinin-Piperaquine. <i>Antimicrobial Agents and Chemotherapy</i> , 2017, 61, .	3.2	16
81	Population Pharmacokinetic and Pharmacodynamic Modeling of Artemisinin Resistance in Southeast Asia. <i>AAPS Journal</i> , 2017, 19, 1842-1854.	4.4	12
82	Quantification of the antimalarial drug pyronaridine in whole blood using LC-MS/MS Increased sensitivity resulting from reduced non-specific binding. <i>Journal of Pharmaceutical and Biomedical Analysis</i> , 2017, 146, 214-219.	2.8	6
83	Population pharmacokinetics and electrocardiographic effects of dihydroartemisinin-piperaquine in healthy volunteers. <i>British Journal of Clinical Pharmacology</i> , 2017, 83, 2752-2766.	2.4	28
84	Estimation of the <i>In Vivo</i> MIC of Cipargamin in Uncomplicated <i>Plasmodium falciparum</i> Malaria. <i>Antimicrobial Agents and Chemotherapy</i> , 2017, 61, .	3.2	27
85	Antibacterial Activities and Possible Modes of Action of <i>Acacia nilotica</i> (L.) Del. against Multidrug-Resistant <i>Escherichia coli</i> and <i>Salmonella</i> . <i>Molecules</i> , 2017, 22, 47.	3.8	59
86	Treatment Failure of Dihydroartemisinin/Piperaquine for <i>Plasmodium falciparum</i> Malaria, Vietnam. <i>Emerging Infectious Diseases</i> , 2017, 23, 715-717.	4.3	76
87	Inhibition of merozoite invasion and transient de-sequestration by sevuparin in humans with <i>Plasmodium falciparum</i> malaria. <i>PLoS ONE</i> , 2017, 12, e0188754.	2.5	41
88	Ivermectin susceptibility and sporontocidal effect in Greater Mekong Subregion <i>Anopheles</i> . <i>Malaria Journal</i> , 2017, 16, 280.	2.3	46
89	<i>In vitro</i> antioxidant and antimalarial activities of leaves, pods and bark extracts of <i>Acacia nilotica</i> (L.) Del.. <i>BMC Complementary and Alternative Medicine</i> , 2017, 17, 372.	3.7	46
90	Population Pharmacokinetic Properties of Piperaquine in <i>Falciparum</i> Malaria: An Individual Participant Data Meta-Analysis. <i>PLoS Medicine</i> , 2017, 14, e1002212.	8.4	50

#	ARTICLE	IF	CITATIONS
91	Na <sup>+</sup> -pooled pharmacokinetic analysis of pyrazinamide, isoniazid and rifampicin in plasma and cerebrospinal fluid of Vietnamese children with tuberculous meningitis. <i>BMC Infectious Diseases</i> , 2016, 16, 144.	2.9	40
92	Pharmacokinetic properties of intramuscular versus oral syrup paracetamol in <i>Plasmodium falciparum</i> malaria. <i>Malaria Journal</i> , 2016, 15, 244.	2.3	4
93	Population pharmacokinetics of oseltamivir and oseltamivir carboxylate in obese and non-obese volunteers. <i>British Journal of Clinical Pharmacology</i> , 2016, 81, 1103-1112.	2.4	19
94	Clinical presentations, diagnosis, mortality and prognostic markers of tuberculous meningitis in Vietnamese children: a prospective descriptive study. <i>BMC Infectious Diseases</i> , 2016, 16, 573.	2.9	46
95	Population Pharmacokinetic Modeling of Tribendimidine Metabolites in <i>Opisthorchis viverrini</i> -Infected Adults. <i>Antimicrobial Agents and Chemotherapy</i> , 2016, 60, 5695-5704.	3.2	9
96	Population pharmacokinetic properties of artemisinin in healthy male Vietnamese volunteers. <i>Malaria Journal</i> , 2016, 15, 90.	2.3	21
97	Clinical trials of artesunate plus sulfadoxine-pyrimethamine for <i>Plasmodium falciparum</i> malaria in Afghanistan: maintained efficacy a decade after introduction. <i>Malaria Journal</i> , 2016, 15, 121.	2.3	8
98	Treatment of Malaria in Pregnancy. <i>New England Journal of Medicine</i> , 2016, 374, 981-982.	27.0	28
99	Dihydroartemisinin-piperaquine resistance in <i>Plasmodium falciparum</i> malaria in Cambodia: a multisite prospective cohort study. <i>Lancet Infectious Diseases</i> , The, 2016, 16, 357-365.	9.1	381
100	Opposite malaria and pregnancy effect on oral bioavailability of artesunate – a population pharmacokinetic evaluation. <i>British Journal of Clinical Pharmacology</i> , 2015, 80, 642-653.	2.4	29
101	The role of previously unmeasured organic acids in the pathogenesis of severe malaria. <i>Critical Care</i> , 2015, 19, 317.	5.8	15
102	Evidence of <i>Plasmodium falciparum</i> Malaria Multidrug Resistance to Artemisinin and Piperaquine in Western Cambodia: Dihydroartemisinin-Piperaquine Open-Label Multicenter Clinical Assessment. <i>Antimicrobial Agents and Chemotherapy</i> , 2015, 59, 4719-4726.	3.2	254
103	Pharmacokinetic Interactions between Primaquine and Pyronaridine-Artesunate in Healthy Adult Thai Subjects. <i>Antimicrobial Agents and Chemotherapy</i> , 2015, 59, 505-513.	3.2	41
104	The effect of dosing strategies on the therapeutic efficacy of artesunate-amodiaquine for uncomplicated malaria: a meta-analysis of individual patient data. <i>BMC Medicine</i> , 2015, 13, 66.	5.5	37
105	Screening of phytochemicals and in vitro evaluation of antibacterial and antioxidant activities of leaves, pods and bark extracts of <i>Acacia nilotica</i> (L.) Del.. <i>Industrial Crops and Products</i> , 2015, 77, 873-882.	5.2	81
106	Randomized Noninferiority Trial of Dihydroartemisinin-Piperaquine Compared with Sulfadoxine-Pyrimethamine plus Amodiaquine for Seasonal Malaria Chemoprevention in Burkina Faso. <i>Antimicrobial Agents and Chemotherapy</i> , 2015, 59, 4387-4396.	3.2	58
107	Lumefantrine and Desbutyl-Lumefantrine Population Pharmacokinetic-Pharmacodynamic Relationships in Pregnant Women with Uncomplicated <i>Plasmodium falciparum</i> Malaria on the Thailand-Myanmar Border. <i>Antimicrobial Agents and Chemotherapy</i> , 2015, 59, 6375-6384.	3.2	27
108	Artemether-Lumefantrine co-administration with antiretrovirals: population pharmacokinetics and dosing implications. <i>British Journal of Clinical Pharmacology</i> , 2015, 79, 636-649.	2.4	44

#	ARTICLE	IF	CITATIONS
109	Efficacy and Day 7 Plasma Piperazine Concentrations in African Children Treated for Uncomplicated Malaria with Dihydroartemisinin-Piperazine. <i>PLoS ONE</i> , 2014, 9, e103200.	2.5	16
110	Spread of Artemisinin Resistance in <i>Plasmodium falciparum</i> Malaria. <i>New England Journal of Medicine</i> , 2014, 371, 411-423.	27.0	1,753
111	Contrasting benefits of different artemisinin combination therapies as first-line malaria treatments using model-based cost-effectiveness analysis. <i>Nature Communications</i> , 2014, 5, 5606.	12.8	85
112	Open-Label Crossover Study of Primaquine and Dihydroartemisinin-Piperazine Pharmacokinetics in Healthy Adult Thai Subjects. <i>Antimicrobial Agents and Chemotherapy</i> , 2014, 58, 7340-7346.	3.2	42
113	Population Pharmacokinetic Assessment of the Effect of Food on Piperazine Bioavailability in Patients with Uncomplicated Malaria. <i>Antimicrobial Agents and Chemotherapy</i> , 2014, 58, 2052-2058.	3.2	22
114	Randomized Comparison of the Efficacies and Tolerabilities of Three Artemisinin-Based Combination Treatments for Children with Acute <i>Plasmodium falciparum</i> Malaria in the Democratic Republic of the Congo. <i>Antimicrobial Agents and Chemotherapy</i> , 2014, 58, 5528-5536.	3.2	35
115	Pharmacokinetic Interactions between Primaquine and Chloroquine. <i>Antimicrobial Agents and Chemotherapy</i> , 2014, 58, 3354-3359.	3.2	78
116	Disposition of amodiaquine and desethylamodiaquine in HIV-infected Nigerian subjects on nevirapine-containing antiretroviral therapy. <i>Journal of Antimicrobial Chemotherapy</i> , 2014, 69, 1370-1376.	3.0	18
117	Benefits of a Pharmacology Antimalarial Reference Standard and Proficiency Testing Program Provided by the Worldwide Antimalarial Resistance Network (WWARN). <i>Antimicrobial Agents and Chemotherapy</i> , 2014, 58, 3889-3894.	3.2	25
118	Characterization of an in vivo concentration-effect relationship for piperazine in malaria chemoprevention. <i>Science Translational Medicine</i> , 2014, 6, 260ra147.	12.4	18
119	Pharmacokinetics of co-formulated mefloquine and artesunate in pregnant and non-pregnant women with uncomplicated <i>Plasmodium falciparum</i> infection in Burkina Faso. <i>Journal of Antimicrobial Chemotherapy</i> , 2014, 69, 2499-2507.	3.0	31
120	Pharmacokinetics of Orally Administered Oseltamivir in Healthy Obese and Nonobese Thai Subjects. <i>Antimicrobial Agents and Chemotherapy</i> , 2014, 58, 1615-1621.	3.2	21
121	Statistical Power Calculations for Mixed Pharmacokinetic Study Designs Using a Population Approach. <i>AAPS Journal</i> , 2014, 16, 1110-1118.	4.4	6
122	Population pharmacokinetics of quinine in pregnant women with uncomplicated <i>Plasmodium falciparum</i> malaria in Uganda. <i>Journal of Antimicrobial Chemotherapy</i> , 2014, 69, 3033-3040.	3.0	22
123	Combination Therapy with Amantadine, Oseltamivir and Ribavirin for Influenza A Infection: Safety and Pharmacokinetics. <i>Antiviral Therapy</i> , 2013, 18, 377-386.	1.0	61
124	Liquid chromatographic-mass spectrometric method for simultaneous determination of small organic acids potentially contributing to acidosis in severe malaria. <i>Journal of Chromatography B: Analytical Technologies in the Biomedical and Life Sciences</i> , 2013, 941, 116-122.	2.3	33
125	A robust design for identification of the Parasite Clearance Estimator. <i>Malaria Journal</i> , 2013, 12, 410.	2.3	9
126	Pharmacokinetic Properties of Anti-Influenza Neuraminidase Inhibitors. <i>Journal of Clinical Pharmacology</i> , 2013, 53, 119-139.	2.0	54

#	ARTICLE	IF	CITATIONS
127	Pharmacokinetic Properties of Artemether, Dihydroartemisinin, Lumefantrine, and Quinine in Pregnant Women with Uncomplicated Plasmodium falciparum Malaria in Uganda. <i>Antimicrobial Agents and Chemotherapy</i> , 2013, 57, 5096-5103.	3.2	41
128	Effect of High-Dose or Split-Dose Artesunate on Parasite Clearance in Artemisinin-Resistant Falciparum Malaria. <i>Clinical Infectious Diseases</i> , 2013, 56, e48-e58.	5.8	48
129	Plasmodium falciparum Drug Resistance Phenotype as Assessed by Patient Antimalarial Drug Levels and Its Association With pfmdr1 Polymorphisms. <i>Journal of Infectious Diseases</i> , 2013, 207, 842-847.	4.0	99
130	Population Pharmacokinetic and Pharmacodynamic Properties of Intramuscular Quinine in Tanzanian Children with Severe Falciparum Malaria. <i>Antimicrobial Agents and Chemotherapy</i> , 2013, 57, 775-783.	3.2	10
131	Reduced Susceptibility of Plasmodium falciparum to Artesunate in Southern Myanmar. <i>PLoS ONE</i> , 2013, 8, e57689.	2.5	177
132	Significant pharmacokinetic interactions between artemether/lumefantrine and efavirenz or nevirapine in HIV-infected Ugandan adults. <i>Journal of Antimicrobial Chemotherapy</i> , 2012, 67, 2213-2221.	3.0	77
133	Lopinavir/ritonavir significantly influences pharmacokinetic exposure of artemether/lumefantrine in HIV-infected Ugandan adults. <i>Journal of Antimicrobial Chemotherapy</i> , 2012, 67, 1217-1223.	3.0	43
134	Population Pharmacokinetic and Pharmacodynamic Modeling of Amodiaquine and Desethylamodiaquine in Women with Plasmodium vivax Malaria during and after Pregnancy. <i>Antimicrobial Agents and Chemotherapy</i> , 2012, 56, 5764-5773.	3.2	44
135	Population Pharmacokinetics of Dihydroartemisinin and Piperaquine in Pregnant and Nonpregnant Women with Uncomplicated Malaria. <i>Antimicrobial Agents and Chemotherapy</i> , 2012, 56, 1997-2007.	3.2	88
136	Randomized, Double-Blind, Placebo-Controlled Trial of Monthly versus Bimonthly Dihydroartemisinin-Piperaquine Chemoprevention in Adults at High Risk of Malaria. <i>Antimicrobial Agents and Chemotherapy</i> , 2012, 56, 1571-1577.	3.2	62
137	Pharmacokinetics of Piperaquine in Pregnant Women in Sudan with Uncomplicated Plasmodium falciparum Malaria. <i>American Journal of Tropical Medicine and Hygiene</i> , 2012, 87, 35-40.	1.4	36
138	The status of pharmacometrics in pregnancy: highlights from the 3 <sup>rd</sup> American conference on pharmacometrics. <i>British Journal of Clinical Pharmacology</i> , 2012, 74, 932-939.	2.4	25
139	A population pharmacokinetic model of piperaquine in pregnant and non-pregnant women with uncomplicated Plasmodium falciparum malaria in Sudan. <i>Malaria Journal</i> , 2012, 11, 398.	2.3	39
140	Population pharmacokinetics of Artemether and dihydroartemisinin in pregnant women with uncomplicated Plasmodium falciparum malaria in Uganda. <i>Malaria Journal</i> , 2012, 11, 293.	2.3	38
141	Optimal designs for population pharmacokinetic studies of the partner drugs co-administered with artemisinin derivatives in patients with uncomplicated falciparum malaria. <i>Malaria Journal</i> , 2012, 11, 143.	2.3	16
142	Artesunate/dihydroartemisinin pharmacokinetics in acute falciparum malaria in pregnancy: absorption, bioavailability, disposition and disease effects. <i>British Journal of Clinical Pharmacology</i> , 2012, 73, 467-477.	2.4	60
143	Orally Formulated Artemisinin in Healthy Fasting Vietnamese Male Subjects: A Randomized, Four-Sequence, Open-Label, Pharmacokinetic Crossover Study. <i>Clinical Therapeutics</i> , 2011, 33, 644-654.	2.5	17
144	Optimal designs for population pharmacokinetic studies of oral artesunate in patients with uncomplicated falciparum malaria. <i>Malaria Journal</i> , 2011, 10, 181.	2.3	14

#	ARTICLE	IF	CITATIONS
145	Intrahost modeling of artemisinin resistance in <i>Plasmodium falciparum</i> . Proceedings of the National Academy of Sciences of the United States of America, 2011, 108, 397-402.	7.1	154
146	Pharmacokinetics of Amodiaquine and Desethylamodiaquine in Pregnant and Postpartum Women with <i>Plasmodium vivax</i> Malaria. Antimicrobial Agents and Chemotherapy, 2011, 55, 4338-4342.	3.2	45
147	A Small Amount of Fat Does Not Affect Piperaquine Exposure in Patients with Malaria. Antimicrobial Agents and Chemotherapy, 2011, 55, 3971-3976.	3.2	26
148	Pharmacokinetics of Dihydroartemisinin and Piperaquine in Pregnant and Nonpregnant Women with Uncomplicated <i>Falciparum</i> Malaria. Antimicrobial Agents and Chemotherapy, 2011, 55, 5500-5506.	3.2	59
149	Comparison of plasma, venous and capillary blood levels of piperaquine in patients with uncomplicated <i>falciparum</i> malaria. European Journal of Clinical Pharmacology, 2010, 66, 705-712.	1.9	30
150	Pharmacokinetics of artemether and dihydroartemisinin in healthy Pakistani male volunteers treated with artemether-lumefantrine. Malaria Journal, 2010, 9, 275.	2.3	27
151	Population Pharmacokinetics of Lumefantrine in Pregnant Women Treated with Artemether-Lumefantrine for Uncomplicated <i>Plasmodium falciparum</i> Malaria. Antimicrobial Agents and Chemotherapy, 2009, 53, 3837-3846.	3.2	96
152	Artemisinin Resistance in <i>Plasmodium falciparum</i> Malaria. New England Journal of Medicine, 2009, 361, 455-467.	27.0	2,873
153	Does Artesunate Prolong the Electrocardiograph QT Interval in Patients with Severe Malaria?. American Journal of Tropical Medicine and Hygiene, 2009, 80, 126-132.	1.4	28
154	Does artesunate prolong the electrocardiograph QT interval in patients with severe malaria?. American Journal of Tropical Medicine and Hygiene, 2009, 80, 126-32.	1.4	18
155	Quantification of the antimalarial piperaquine in plasma. Transactions of the Royal Society of Tropical Medicine and Hygiene, 2008, 102, 409-411.	1.8	10
156	Pitfalls in Estimating Piperaquine Elimination. Antimicrobial Agents and Chemotherapy, 2005, 49, 5127-5128.	3.2	63
157	Determination of ceftriaxone in human plasma using liquid chromatography-tandem mass spectrometry. Wellcome Open Research, 0, 4, 47.	1.8	2
158	Determination of ceftriaxone in human plasma using liquid chromatography-tandem mass spectrometry. Wellcome Open Research, 0, 4, 47.	1.8	5
159	Population pharmacokinetics of artesunate and dihydroartemisinin in pregnant and non-pregnant women with uncomplicated <i>Plasmodium falciparum</i> malaria in Burkina Faso: an open label trial. Wellcome Open Research, 0, 4, 45.	1.8	0
160	Determination of ceftriaxone in human plasma using liquid chromatography-tandem mass spectrometry. Wellcome Open Research, 0, 4, 47.	1.8	3